Alex­ion is re­or­ga­niz­ing R&D, ax­ing 600-plus jobs and mov­ing HQ to Boston as ex­ecs prep deal spree

The new crew in charge of Alex­ion $ALXN is pulling up stakes from New Haven, CT and mov­ing its head­quar­ters to the big bio­phar­ma hub in Boston/Cam­bridge. And the dra­mat­ic move will come with some big lay­offs.

In a top-to-bot­tom re­vamp, Alex­ion CEO Lud­wig Hantson an­nounced plans to down­size R&D as it re­or­ga­nized the pipeline. The bio­phar­ma com­pa­ny al­so plans to shut­ter a va­ri­ety of fa­cil­i­ties, in­clud­ing the Alex­ion Rhode Is­land man­u­fac­tur­ing fa­cil­i­ty and “cer­tain re­gion­al and coun­try-based of­fices.” And it will spend up to $440 mil­lion in a shake­up that in­cludes lay­offs in the com­mer­cial group as well as ad­min­is­tra­tive of­fices as it moves 400 jobs to Boston.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER